Caladrius Biosciences (NASDAQ:CLBS) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Caladrius Biosciences (NASDAQ:CLBSGet Rating) in a research note published on Tuesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, HC Wainwright dropped their price target on Caladrius Biosciences from $8.00 to $6.00 and set a buy rating on the stock in a research report on Wednesday, March 23rd.

CLBS stock opened at $0.68 on Tuesday. The stock’s fifty day simple moving average is $0.73 and its two-hundred day simple moving average is $0.89. Caladrius Biosciences has a 1-year low of $0.63 and a 1-year high of $1.71. The stock has a market cap of $40.65 million, a P/E ratio of -1.31 and a beta of 0.97.

Caladrius Biosciences (NASDAQ:CLBSGet Rating) last posted its quarterly earnings data on Tuesday, March 22nd. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.03. During the same period in the previous year, the firm posted ($0.28) earnings per share. As a group, equities research analysts forecast that Caladrius Biosciences will post -0.41 earnings per share for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of CLBS. Renaissance Technologies LLC raised its stake in shares of Caladrius Biosciences by 11.8% during the 3rd quarter. Renaissance Technologies LLC now owns 1,747,055 shares of the biotechnology company’s stock valued at $2,131,000 after purchasing an additional 184,223 shares during the period. Virtu Financial LLC bought a new stake in shares of Caladrius Biosciences during the 4th quarter valued at $135,000. Alterna Wealth Management Inc. bought a new stake in shares of Caladrius Biosciences during the 4th quarter valued at $61,000. Morgan Stanley raised its stake in shares of Caladrius Biosciences by 533.0% during the 1st quarter. Morgan Stanley now owns 70,537 shares of the biotechnology company’s stock valued at $137,000 after purchasing an additional 59,393 shares during the period. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Caladrius Biosciences during the 2nd quarter valued at $87,000. 17.06% of the stock is currently owned by hedge funds and other institutional investors.

About Caladrius Biosciences (Get Rating)

Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. Its product pipeline includes CLBS12, CLBS14, CLBS16 and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.

Featured Stories

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.